|
⚲
|
| Keyboard |
| Natixis Private Equity
✚
|
|
|---|---|
| CIK # | 0001620390 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001620390] | |
| 4 | [0001620390] | |
| SC 13G | [0001620390] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Natixis Private Equity | Eyegate Pharmaceuticals Inc | [2015-03-04] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Natixis Private Equity | |
| Kiora Pharmaceuticals Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Kiora Pharmaceuticals Inc EYEG
Common Stock
|
2015-02-19 | Conversion | 576,564 | ||
|
Kiora Pharmaceuticals Inc EYEG
Common Stock
|
2015-02-19 | Conversion | 97,641 | $4.20 | 410,092 |
|
Kiora Pharmaceuticals Inc EYEG
Series D Preferred Stock · derivative
|
2015-02-19 | Conversion | 576,564 | $0.00 | |
|
Kiora Pharmaceuticals Inc EYEG
Convertible Promissory Note · derivative
|
2015-02-19 | Buy | $410,092.00 | ||
|
Kiora Pharmaceuticals Inc EYEG
Convertible Promissory Note · derivative
|
2015-02-19 | Conversion | $0.00 |